CinFina Pharma announced positive topline interim data from its Phase 1 single ascending dose (SAD) study of CIN-110 and final data from its multiple ascending dose (MAD) study of CIN-109, both indicating tolerability and significant weight loss potential. These findings, presented at ObesityWeek® 2024, highlight the promise of next-generation mechanisms for obesity treatment.
CIN-110: PYY3-36 Analog for Reduced Caloric Intake
CIN-110, a novel, long-acting peptide YY (PYY3-36) analog, is designed to minimize gastrointestinal side effects commonly associated with PYY-based therapies. The Phase 1 SAD study involved 24 obese participants (mean BMI ~34 kg/m2) and demonstrated that a single subcutaneous dose of CIN-110 led to a reduction in food intake by up to 28% and a body weight decrease of up to 1.8% within one week. The drug exhibited a gradual increase in concentration, reaching peak levels within two to three days and sustaining an approximate 14-day half-life. Reported side effects were mild, with three cases of mild nausea resolving quickly, and no participants withdrew due to adverse events.
CIN-109: GDF-15 Analog for Fat Mass Reduction
CIN-109, a novel, long-acting, first-in-class growth differentiation factor 15 (GDF-15) analog, aims to decrease appetite, maintain energy expenditure, and drive weight loss while preserving lean body mass. In the Phase 1 MAD study, obese participants (mean BMI ~35 mg/m2) received weekly or bi-weekly doses of CIN-109. Results showed dose-dependent reductions in food intake (up to 50%) and weight loss (up to 3.7%) within one to two months. Bi-weekly dosing was better tolerated, with the majority of weight loss attributed to fat mass reduction. No serious treatment-related side effects were observed.
Clinical Implications and Future Directions
According to CinRx Founder and CEO Jon Isaacsohn, weight loss drugs generate over $6 billion annually, with projections reaching $150 billion by 2030. The early-stage results from CIN-110 and CIN-109 suggest that these next-generation approaches could overcome the limitations of current therapies. CIN-109 is Phase 2 ready and is being further developed to assess its long-term efficacy and safety.
"CIN-110’s ability to help safely and tolerably reduce caloric intake while quickly decreasing body weight after just a single dose distinguishes it as a high-potential candidate. Similarly, CIN-109’s significant impact on fat mass reduction and preservation of lean mass, especially at the highest doses, positions it as a powerful long-term solution,", said Jon Isaacsohn.
